A delayed clinical trial actually boosted Bristol Myers Squibb’s stock.
Here’s why.
-
Bristol Myers’ stock rallied Wednesday as investors maintained high hopes
for Cobenfy as an Alzheimer’s treatment, even though the outcome of a
late-stage ...
42 minutes ago







TERMS AND CONDITIONS MATTER, ... The terms he gets are very favorable to him," said Richard Bernstein, former chief investment strategist at Merrill Lynch and current CEO of investment advisory Richard Bernstein Advisors.
ReplyDelete